OA09671A - Synthetic polypeptides - Google Patents

Synthetic polypeptides

Info

Publication number
OA09671A
OA09671A OA60275A OA60275A OA09671A OA 09671 A OA09671 A OA 09671A OA 60275 A OA60275 A OA 60275A OA 60275 A OA60275 A OA 60275A OA 09671 A OA09671 A OA 09671A
Authority
OA
OAPI
Prior art keywords
synthetic polypeptides
polypeptides
synthetic
Prior art date
Application number
OA60275A
Other languages
English (en)
Inventor
Robert Vincent Fishleigh
Barry Robson
Original Assignee
Proteus Molecular Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Molecular Design filed Critical Proteus Molecular Design
Publication of OA09671A publication Critical patent/OA09671A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA60275A 1990-03-15 1992-09-11 Synthetic polypeptides OA09671A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909005829A GB9005829D0 (en) 1990-03-15 1990-03-15 Synthetic polypeptides

Publications (1)

Publication Number Publication Date
OA09671A true OA09671A (en) 1993-05-15

Family

ID=10672665

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60275A OA09671A (en) 1990-03-15 1992-09-11 Synthetic polypeptides

Country Status (17)

Country Link
EP (1) EP0519986A1 (fr)
JP (1) JPH05505188A (fr)
CN (1) CN1054772A (fr)
AP (1) AP211A (fr)
AU (1) AU636735B2 (fr)
BR (1) BR9106159A (fr)
CA (1) CA2078220A1 (fr)
CS (1) CS68091A2 (fr)
FI (1) FI923800A0 (fr)
GB (1) GB9005829D0 (fr)
HU (1) HUT63179A (fr)
IL (1) IL97551A0 (fr)
MX (1) MX24890A (fr)
NZ (1) NZ237417A (fr)
OA (1) OA09671A (fr)
WO (1) WO1991013909A1 (fr)
ZA (1) ZA911886B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009252A1 (fr) * 1991-11-04 1993-05-13 Baxter Diagnostics Inc. Peptides synthetiques correspondant a des portions du virus vih-2 et procedes d'utilisation de ces peptides dans une analyse amelioree
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
NZ249789A (en) * 1992-03-11 1997-07-27 Narhex Ltd Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
GB9208428D0 (en) * 1992-04-16 1992-06-03 Proteus Molecular Design Synthetic polypeptides
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
JP4116072B2 (ja) 1992-08-27 2008-07-09 バイオクローンズ(プロプライエタリー)リミテッド 逆向き、鏡像体および逆向き鏡像体合成ペプチド類似物
DE4402756A1 (de) * 1994-01-31 1995-08-03 Boehringer Mannheim Gmbh Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6290971B1 (en) 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
CN1472314A (zh) * 2002-07-29 2004-02-04 清华大学 艾滋病病毒o型株的一个免疫学表位及其应用
CN100445296C (zh) * 2006-03-31 2008-12-24 浙江大学 多肽有机化合物及其在异种移植中的应用
WO2010057197A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs méthodes d’utilisation
GB201612108D0 (en) 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
ATE87487T1 (de) * 1987-11-16 1993-04-15 Hoffmann La Roche Rekombinante hiv-2 polypeptide.

Also Published As

Publication number Publication date
MX24890A (es) 1993-12-01
NZ237417A (en) 1993-10-26
ZA911886B (en) 1991-12-24
JPH05505188A (ja) 1993-08-05
WO1991013909A1 (fr) 1991-09-19
CA2078220A1 (fr) 1991-09-16
FI923800A (fi) 1992-08-24
BR9106159A (pt) 1993-03-16
IL97551A0 (en) 1992-06-21
AU7467991A (en) 1991-10-10
AU636735B2 (en) 1993-05-06
HUT63179A (en) 1993-07-28
GB9005829D0 (en) 1990-05-09
AP211A (en) 1992-10-21
HU9202939D0 (en) 1992-12-28
EP0519986A1 (fr) 1992-12-30
CN1054772A (zh) 1991-09-25
FI923800A0 (fi) 1992-08-24
AP9100245A0 (en) 1991-04-30
CS68091A2 (en) 1991-12-17

Similar Documents

Publication Publication Date Title
IL95071A0 (en) Synthetic material-bottle
GB9005829D0 (en) Synthetic polypeptides
GB9208428D0 (en) Synthetic polypeptides
EP0447133A3 (en) Paired polypeptides
GB9016810D0 (en) Peptides
ZW9093A1 (en) Synthetic polypeptides
GB9106674D0 (en) Synthetic polypeptides
ZA929392B (en) Synthetic polypeptides
GB9009623D0 (en) Polypeptides
GB9013773D0 (en) Polypeptides
GB9016215D0 (en) Polypeptides
ZA935308B (en) Synthetic polypeptides
GB9219710D0 (en) Synthetic polypeptides
GB9218163D0 (en) Synthetic polypeptides
GB9214663D0 (en) Synthetic polypeptides
IE892648L (en) Synthetic polypeptides
ZA914206B (en) Crystalline polypeptides
GB9105871D0 (en) Synthetic peptides
GB8816991D0 (en) Synthetic polypeptides
GB8804656D0 (en) Synthetic polypeptides
GB8816987D0 (en) Synthetic polypeptides
GB8816988D0 (en) Synthetic polypeptides
GB8816989D0 (en) Synthetic polypeptides
GB8816990D0 (en) Synthetic polypeptides
GB8804657D0 (en) Synthetic polypeptides